DALMAXIN

INSTRUCTIONS for medical use of the medicinal product DALKSIN (DALMAXIN)

Composition:

Active substance: 1 g of ointment contains tiotriazolin (calculated as 100% substance) – 20 mg;

Excipients: methylcellulose, glycerol, methylparahydroxybenzoate (E 218), propylparahydroxybenzoate (E 216), purified water.

Pharmaceutical form. Ointment.

Main physicochemical properties: colorless or slightly grayish ointment. Opalescence is permissible.

Pharmacotherapeutic group.

Agents for the treatment of wounds and ulcerative lesions.

ATC code D03AX.

Pharmacological properties.

Pharmacodynamics.

The pharmacotherapeutic effect of tiothiazolin is due to its membrane-stabilizing properties, inhibition of lipid peroxidation processes, and activation of antioxidant defense enzymes in damaged skin and mucous tissues, resulting in suppression of traumatic inflammation development, enhanced intensity and rate of reparative processes, and reduced wound healing time.

Pharmacokinetics.

Tiothiazolin is practically not absorbed following application to the skin and does not enter the systemic circulation.

The drug is sufficiently rapidly absorbed through the oral mucosa, and its maximum plasma concentration is reached within 1.5 hours.

Clinical characteristics.

Indications.

Wounds with delayed healing, slow granulation and epithelialization, trophic ulcers and pressure sores. Psoriasis. Inflammatory dystrophic forms of periodontitis and ulcerative lesions of the oral mucosa and gums.

Contraindications.

Hypersensitivity to the components of the drug.

Special precautions.

The drug should be used after surgical wound debridement, removal of necrotic tissues, and antiseptic treatment of the wound surface.

Interaction with other medicinal products and other forms of interaction.

Thiotriazolin can be used in combination with other anti-inflammatory, antiseptic, and chemotherapeutic agents.

Special precautions.

Use during pregnancy or breastfeeding.

No contraindications.

Ability to affect reaction speed when driving or operating machinery.

Does not affect.

Method of administration and dosage.

For external use. Apply the ointment as a thin layer on the skin wound surface, under a dressing or in an open manner, 1–2 times daily for 1–3 weeks.

In case of inflammatory dental diseases, insert the ointment into the gingival pockets 1–2 times daily for 1–2 weeks.

Children.

No contraindications.

Overdose.

Overdose is unlikely.

Side effects.

Possible hypersensitivity reactions, including itching, rash, skin hyperemia, fever, urticaria, angioneurotic edema.

Shelf life. 2 years.

Do not use after the expiry date stated on the packaging.

Storage conditions.

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging.

25 g of ointment in tubes № 1; in a cardboard box.

Supply category.

Over-the-counter.

Manufacturer.

JSC "CHEMICAL PHARMACEUTICAL PLANT "CHERVONA ZIRKA".

Manufacturer's address.

1, Gordienkovska Street, Kharkiv, Kharkiv region, 61010, Ukraine.